China’s Payer Keeps Deep Price Cuts Steady in Latest NRDL Listing
Volume/Pricing Trade-Off
The 2022 pricing negotiations for innovative drugs organized by China’s National Healthcare Security Administration have slashed prices of included products by 60% on average, a level mostly unchanged from the 2021 round, although 36% more novel medicines were covered.
